Status:
RECRUITING
Outcomes After Intravenous Alteplase / Tenecteplase With or Without Shuxuetong Injection in Routine Clinical Practice
Lead Sponsor:
Dongzhimen Hospital, Beijing
Conditions:
Ischemic Stroke, Acute
Eligibility:
All Genders
18+ years
Brief Summary
Acute ischemic stroke is one of the main diseases leading to high risk of disability and morbidity worldwide. Since intravenous thrombolysis(IVT) can effectively improve the long-term functional progn...
Eligibility Criteria
Inclusion
- Hospitalized patients aged ≥18 years
- Diagnosis of acute ischemic stroke
- Receiving alteplase or tenecteplase treatment ≤ 4.5 hours of onset
- Signed informed consent by patient or legally authorized representatives
Exclusion
- Having received or planing to undergo endovascular therapy (including mechanical thrombectomy, arterial thrombolysis, angioplasty, etc.)
- Life expectancy is less than 90 days
- Other factors that the researchers think are not suitable for participating in the research
- Currently receiving any experimental treatment
Key Trial Info
Start Date :
September 28 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
2008 Patients enrolled
Trial Details
Trial ID
NCT06018181
Start Date
September 28 2023
End Date
December 31 2025
Last Update
November 28 2025
Active Locations (78)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Royal Integrative Medicine Hospital
Beijing, Beijing Municipality, China
2
China Aerospace Science and Industry Corporation 731 Hospital
Beijing, Beijing Municipality, China
3
Chongqing Chinese Medicine Hospital
Chongqing, Chongqing Municipality, China
4
University-Town Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China